Kalaris Therapeutics (KLRS) vs Genenta Science S.p.A. (SAEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $24.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | SAEN |
|---|---|---|
| Share price | $1.28 | $0.5074 |
| Market cap | $30.47M | $24.47M |
| 1-day change | -5.19% | -9.39% |
| YTD return | -84.83% | — |
| 1-year return | -81.74% | — |
| 5-year return | -99.70% | — |
| EPS (TTM) | $-1.84 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-43.44M | — |
| 52-week high | $11.88 | $2.58 |
| 52-week low | $1.25 | $0.50 |
| Distance from 52-week high | -89.23% | -80.33% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1361.72% | — |
| Average volume | 77.37K | 85.01K |
| Shares outstanding | 23.80M | 48.22M |
| Employees | 20 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Genenta Science S.p.A.
SAEN stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees
KLRS vs SAEN FAQ
Which is bigger, Kalaris Therapeutics or Genenta Science S.p.A.?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $24.47M for Genenta Science S.p.A. (SAEN).
Are Kalaris Therapeutics and Genenta Science S.p.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.